PERSPECTIVE THERAPEUTICS, INC. Debt Securities, Available-for-sale, Unrealized Loss
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported Debt Securities, Available-for-sale, Unrealized Loss of $229.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2026-08-10
- PERSPECTIVE THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2026-06-30 was -$12.00K.
- PERSPECTIVE THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2026-03-31 was $241.00K, a 677.42% increase year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-12-31 was -$2.00K.
- PERSPECTIVE THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-09-30 was -$25.00K.
- PERSPECTIVE THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for fiscal 2024 was $73.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $229.00K 10-Q · filed 2026-08-10 | $227.00K derived: sum of 3 quarters · filed 2026-08-10 | $202.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $241.00K 10-Q · filed 2026-05-11 | $239.00K derived: sum of 2 quarters · filed 2026-08-10 | $214.00K derived: sum of 3 quarters · filed 2026-08-10 | $214.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$2.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-10 | -$27.00K derived: sum of 2 quarters · filed 2026-08-10 | -$27.00K derived: sum of 3 quarters · filed 2026-08-10 | $4.00K 10-Q · filed 2026-08-10 |
| 2025-09-30 | -$25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$25.00K derived: sum of 2 quarters · filed 2025-11-10 | $6.00K 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $31.00K 10-Q · filed 2025-08-13 | ||
| 2025-03-31 | $31.00K 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | $73.00K 10-K · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |